Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
AssigneeAmgen Inc.
InventorsScott M. Silbiger, Raymond A. Koski
Life of this patent
Estimating the term…
Abstract
The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such inhibitors. In particular, the invention relates to novel mammalian inhibitors of metalloproteinase, which are designated as type three or TIMP-3, to fragments, derivatives, and analogs thereof, and to polynucleotides encoding the same. Novel methods of producing such compositions and novel methods of using such compositions are also provided.
Claims9
A composition comprising an isolated DNA sequence encoding a human recombinant tissue inhibitor of metalloproteinase 3 polypeptide (recombinant TIMP-3 polypepetide) and a pharmaceutically acceptable carrier, wherein the recombinant TIMP-3 polypeptide is:
- (a) a polypeptide comprising the amino acid sequence 1 to 211 of SEQ ID NO:
- 13;
- (b) a polypeptide comprising the amino acid sequence 24 to 211 of SEQ ID NO:
- 13;
- (c) a polypeptide comprising the amino acid sequence 24 to 144 of SEQ ID NO:
- 13 and, optionally, at the C-terminus, all or part of the amino acid sequence 145–211 of SEQ ID NO:
- 13;
- or
- (d) a polypeptide according to (b) or (c) additionally comprising a methionyl residue at position −1.
A composition comprising an isolated DNA sequence according to SEQ ID NO:
- 12 and a pharmaceutically acceptable carrier, wherein the DNA sequence encodes a polypeptide comprising the amino acid sequence 24 to 211 of SEQ ID NO:
- 13 and, optionally, a methionyl residue at position −1.
An antisense DNA according to all or part of SEQ ID NO:
- 12, wherein the antisense DNA modulates or prevents expression of endogenous human TIMP-3 nucleic acids.
An article of manufacture comprising a packaging material and a pharmaceutical agent, wherein said pharmaceutical agent contains a DNA encoding human TIMP-3, wherein the DNA encoding human TIMP-3 comprises a nucleic acid sequence selected from SEQ ID NO:
- 12, SEQ ID NO:
- 14, and SEQ ID NO:
- 16, and wherein said packaging material comprises a label which indicates that said pharmaceutical composition may be used for an indication benefiting from genetic therapy using such DNA.
A kit comprising a DNA encoding human TIMP-3 and one or more additional factors affecting the ex vivo growth of cells transformed or transfected with said DNA, wherein the DNA encoding human TIMP-3 comprises a nucleic acid sequence selected from SEQ ID NO:
- 12, SEQ ID NO:
- 14, and SEQ ID NO:
- 16, and wherein the one or more additional factors is selected from cytokines and growth factors.
Dependencies are inferred from the claim text.